INTRODUCTION
============

Benign prostatic hyperplasia (BPH) is a pathologic process that is one of the causes of lower urinary tract symptoms (LUTS) in aging men. BPH may cause symptoms including LUTS, benign prostatic enlargement, and bladder outlet obstruction. BPH has similar risk factors to those of prostate cancer \[[@b1-inj-1632538-269]\]. Epithelial cell proliferation in prostate tissue is a major pathologic feature of BPH \[[@b2-inj-1632538-269]\]. Epidermal growth factor (EGF) is linked to the growth and differentiation of epithelial cells. The relationship between EGF and prostate cancer has been previously studied. EGF, vascular endothelial growth factor, fibroblast growth factor 2, transforming growth factor beta 1, and insulin-like growth factor 1 are known to influence the development of both prostate cancer and BPH \[[@b3-inj-1632538-269],[@b4-inj-1632538-269]\], and both conditions share risk factors. However, the relationship between BPH and EGF remains unclear \[[@b1-inj-1632538-269]\].

Evidence has emerged suggesting that the action of EGF is involved in prostate cell growth. EGF expression is promoted by exposure to androgens, such as testosterone and dihydrotestosterone \[[@b5-inj-1632538-269]-[@b7-inj-1632538-269]\]. EGF may cause elevations in E-cadherin, which may promote the phosphorylation of epidermal growth factor receptor (EGFR) and cell proliferation signals \[[@b8-inj-1632538-269]\]. Recent studies have shown that the inhibition of EGFR was linked to decreased proliferation signals to prostatic epithelial cell lines \[[@b9-inj-1632538-269]\].

Although several studies have investigated EGF, only 1 polymorphism in the *EGF* gene has been reported to affect the development of prostate cancer. Teixeira et al. \[[@b10-inj-1632538-269],[@b11-inj-1632538-269]\] reported that the *EGF* +61G\>A polymorphism may contribute to prostate cancer susceptibility and androgen insensitivity. Studies of the *EGFR* gene have shown the features or development of prostate cancer to be associated with various exon mutations \[[@b12-inj-1632538-269],[@b13-inj-1632538-269]\] and single-nucleotide polymorphisms (SNPs) including rs17172432 \[[@b14-inj-1632538-269]\], rs6964705 in the *EGFR* gene combined with rs1401862 in the matrix metallopeptidase 16 (*MMP16*) gene \[[@b15-inj-1632538-269]\], and rs884419 \[[@b16-inj-1632538-269]\].

Although the above studies support a relationship between EGF signals and proliferative prostate disease, no study has investigated the relationship of BPH with the *EGF* and *EGFR* genes. In the present study, we investigated the relationship between SNPs of the *EGF* and *EGFR* genes and the clinical features of BPH in a Korean population.

MATERIALS AND METHODS
=====================

Study Subjects
--------------

All subjects were recruited from the Kyung Hee University Medical Center of Kyung Hee University in Seoul, Korea. This study was approved by Institutional Review Board of Kyung Hee University Medical Center in 2009 (KMC IRB 0913-03). A total of 218 BPH patients diagnosed by a physician were selected ([Table 1](#t1-inj-1632538-269){ref-type="table"}). The criteria for diagnosing BPH included prostate weight (\>20 g) and LUTS. The prostate-specific antigen (PSA) level in the serum of BPH patients was tested and prostate volume was measured using transrectal ultrasonography by urologists. LUTS were quantified using the International Prostate Symptom Score (IPSS). The subjects were dichotomized according to the criteria used in several multicenter studies: low (0--19) and high (≥ 20) IPSS score, low (\<1.5 ng/mL) and high (≥1.5 ng/mL) PSA level, and small (\<30 mL) and large (≥30 mL) prostate volume. Voiding symptoms were classified using the IPSS score as mild (0--7), moderate (8--19), or severe (20--35).

The exclusion criteria were prostate cancer, neurogenic bladder, urinary tract infection, uncontrolled diabetes mellitus, and cardiovascular disease.

Written informed consent was obtained from all participants. Blood samples were collected in tubes containing ethylenediaminetetraacetic acid as an anticlotting factor and stored at −20°C until use. Genomic DNA was extracted using a blood extraction kit (Roche, Indianapolis, IN, USA).

SNP Selection and Genotyping
----------------------------

The National Center for Biotechnology Information SNP database was searched to select SNPs of the *EGF* and *EGFR* genes for study (<http://www.ncbi.nlm.nih.gov/SNP>, BUILD 141). The criteria for the selection of exonic SNPs and promoter SNPs in each gene were the following: (1) \>10% minor allele frequency, (2) \>0.1 heterozygosity, (3) known genotype frequencies in the Asian population, and (4) previous studies. We ultimately selected 5 SNPs of the *EGF* gene (rs3756261, -1744 A/G; rs11568835, -1380 G/A; rs11568943, Arg431Lys; rs2237051, Met708Ile; and rs11569017, Asp784Val) and 3 SNPs of the *EGFR* gene (rs6965469, -2004 C/T; rs2293347, Asp994Asp; and rs1050171, Gln787Gln). Additionally, the genotype of each SNP was determined through direct sequencing after polymerase chain reaction (PCR). PCR primers are shown in [Table 2](#t2-inj-1632538-269){ref-type="table"}. Sequence data were analyzed using SeqManII software (v2.3; DNAATAR Inc., Madison, WI, USA).

Statistical Analysis
--------------------

The derivation of tested SNPs in Hardy-Weinberg equilibrium was evaluated using SNPstats (<http://bioinfo.iconcologia.net/snpstats/start.htm>). Differences in the genotypes and alleles of each SNP were analyzed by SNPstat and IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA). The chi-square test and logistic regression with codominant, dominant, recessive, and log-additive models were utilized to analyze the association between tested polymorphisms and prostate volume, PSA level, or IPSS \[[@b17-inj-1632538-269],[@b18-inj-1632538-269]\]. The linkage disequilibrium (LD) block and haplotypes between pairs of SNPs in each gene were tested using Haploview ver. 4.2 (Daly Laboratory, Cambridge, MA, USA). P-values \<0.05 were considered to indicate statistical significance.

RESULTS
=======

The demographic and biochemical characteristics of the participants are shown in [Table 1](#t1-inj-1632538-269){ref-type="table"}. We analyzed the relationships between polymorphisms of the *EGF* and *EGFR* genes and BPH. The BPH patients were dichotomized according to prostate volume, IPSS score, and PSA level \[[@b19-inj-1632538-269],[@b20-inj-1632538-269]\]. The genotype and allele distributions of the tested SNPs are shown in [Tables 3](#t3-inj-1632538-269){ref-type="table"} and [4](#t4-inj-1632538-269){ref-type="table"} for each group. The derivation of the tested SNPs remained in Hardy-Weinberg equilibrium (rs3756261, P =0.35; rs11568835, P=0.30; rs11568943, P=0.23; rs2237051, P=0.51; rs11569017, P=0.28; and rs2293347, P=0.48 in the *EGF* gene; rs1050171, P=0.88; and rs6965469, P=0.65 in the *EGFR* gene).

First, we analyzed the relationship between polymorphisms of the *EGF* and *EGFR* genes and prostate volume. Codominant, dominant, recessive, and log-additive models were applied for statistical analysis. We found that *EGF* polymorphisms were associated with prostate volume in BPH patients ([Table 3](#t3-inj-1632538-269){ref-type="table"}). The distributions of the G allele of rs11568943 and the A allele of rs11569017 in the *EGF* gene were significantly higher in patients with a prostate volume ≥30 mL than in patients with a prostate volume \<30 mL (rs11568943, P=0.024 and rs11569017, P=0.02). The genotype distributions of *EGF* polymorphisms also showed significant associations with prostate volume (rs11568943, P =0.038 in the log-additive model \[G/G vs. A/G vs. A/A\]; rs11569017, P=0.031 in the dominant model \[A/A vs. A/T+T/T\] and P=0.028 in the log-additive model \[A/A vs. A/T vs. T/T\]). In order to analyze haplotypes, we tested the LD block between paired SNPs in each gene. One LD block was found in the *EGF* gene among 3 SNPs (rs11568943, rs2237051, and rs11569017), and the LD block was strong (rs11568943 and rs2237051, D'=1.0, r^2^=0.109; rs11568943 and rs11569017, D' =0.985, r^2^=0.812; rs2237051 and rs11569017, D'=1.0, r^2^=0.131). Four haplotypes were found in the LD block of the *EGF* gene. Among these haplotypes, a significant difference were found according to AAT haplotype frequency in prostate volume (\<30 mL or ≥30 mL) (P=0.017) ([Table 5](#t5-inj-1632538-269){ref-type="table"}).

Second, we evaluated the relationship between polymorphisms of the *EGF* and *EGFR* genes and PSA levels, and found significant associations ([Table 4](#t4-inj-1632538-269){ref-type="table"}). Three SNPs (rs3756261, -1744 A/G; rs11568943, Arg431Lys; and rs11569017, Asp784Val) in the *EGF* gene showed significant associations. The distributions of the major alleles of rs3756261 and rs11568943 were higher in patients with a PSA level ≥1.5 ng/mL than in patients with PSA levels \<1.5 ng/mL (rs3756261, P =0.011; rs11568943, P=0.021). The genotype distributions of *EGF* polymorphisms also displayed significant differences (rs3756261, P=0.016 in the codominant 1 model \[A/A vs. A/G\], P=0.013 in the dominant model \[A/A vs. A/G+G/G\], P=0.020 in the log-additive model \[A/A vs. A/G vs. G/G\]; rs11568943, P=0.031 in the codominant 1 model \[G/G vs. G/A\], P=0.027 in the dominant model \[G/G vs. G/A+A/A\], P=0.036 in the log-additive model \[G/G vs. G/A vs. A/A\]; rs11569017, P=0.044 in the dominant model \[A/A vs. A/T+T/T\]). Additionally, rs2293347 in the *EGFR* gene showed a relationship with PSA (P=0.044 in the dominant model \[G/G vs. G/A+A/A\], P=0.020 in the log-additive model \[G/G vs. G/A vs. A/A\], and P=0.043 in the allele distribution\]. In the haplotype analysis, a significant association was found between the AAT haplotype in the *EGF* gene and PSA levels (P=0.015) ([Table 5](#t5-inj-1632538-269){ref-type="table"}).

However, we did not find any significant associations between polymorphisms of the *EGF* and *EGFR* genes and IPSS.

DISCUSSION
==========

The pathogenesis of BPH is still unknown. However, several studies have reported that specific polymorphisms in various genes contribute to the pathogenesis of BPH \[[@b21-inj-1632538-269]\]. The most representative genes of this type is the androgen receptor (AR) gene. AR is a transactivation factor that depends on the binding of steroid hormones. It has an important role in the proliferation and differentiation of prostate cells \[[@b22-inj-1632538-269]\]. Polymorphic variations are present in the *AR* gene. It has been suggested that the presence of a higher number of polymorphic GGC repeats in the *AR* gene is associated with an increased risk of developing BPH \[[@b23-inj-1632538-269]\]. Short CAG alleles may be a genetic factor that promotes the growth of BPH \[[@b24-inj-1632538-269]\].

The relationship between *EGF* and *EGFR* polymorphisms and the clinical features of BPH has not been previously investigated. In the current study, associations between SNPs in the *EGF* and *EGFR* genes and BPH were evaluated. The prostate volume of BPH patients was associated with the *EGF* SNPs rs11568943 and rs11569017, and PSA levels in BPH patients were associated with the *EGF* SNPs rs11568943, rs11569017, and rs3756261 and the EGFR SNP rs2293347.

In previous studies of the *EGF* and *EGFR* genes, the rs 11568943 SNP was significantly associated with preeclampsia \[[@b25-inj-1632538-269]\], psoriatic arthritis \[[@b26-inj-1632538-269]\], and gastric cancer \[[@b27-inj-1632538-269]\]. The rs11569017 SNP was associated with the risk of hepatitis B virus-related hepatocellular carcinoma \[[@b28-inj-1632538-269]\]. The rs3756261 SNP was also showed a significant association with a higher risk of developing preeclampsia \[[@b25-inj-1632538-269]\]. Among the *EGFR* SNPs, the rs2293347 SNP is associated with chemotherapeutic response, lung cancer treated with gefitinib, and airway hyperresponsiveness.

EGF binding induces the dimerization of EGFR and the activation of downstream signaling pathways involved in regulating cellular proliferation, differentiation, and survival \[[@b29-inj-1632538-269]\]. This EGF-EGFR ligand-receptor complex stimulates cell proliferation \[[@b30-inj-1632538-269]\]. EGF protects epithelial cells against Fas-induced apoptosis \[[@b31-inj-1632538-269]\], and EGFR plays an essential role in the morphogenesis of mammary glands \[[@b32-inj-1632538-269]\]. EGF controls myoepithelial cell differentiation in mammary gland cultures \[[@b33-inj-1632538-269]\] and EGFR is closely linked to smooth cell apoptosis \[[@b34-inj-1632538-269]\]. The prostate gland consists of the peripheral zone, central zone, and transition zone. The transition zone, which contains smooth muscle cells and myoepithelial cells, is responsible for BPH \[[@b35-inj-1632538-269]\]. As described above, EGF and EGFR may be related to various aspects of epithelial and muscular proliferation, which could affect BPH.

In summary, no associations between the *EGF* and *EGFR* genes and the clinical features of BPH have previously been reported. We found for the first time that 2 SNPs (rs11568943 and rs11569017) and the AAT haplotype in the *EGF* gene may affect prostate volume, and that 3 SNPs (rs11568943, rs11569017, and rs3756261) and the AAT haplotype in *EGF* gene, as well as 1 SNP in the *EGFR* gene (rs2293347), may affect PSA levels in BPH patients. However, this study has limitations such as sample size, ethnic differences, lack of control subjects, and interaction with environmental factors. To confirm our results, a casecontrol study in another population with a larger sample size is needed, as well as a meta-analysis.
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###### 

Demographic and biochemical characteristics of the benign prostatic hyperplasia patients

  Characteristic         Value
  ---------------------- ----------------
  No. of subject         218
  Age (yr)               65.6±10.3
  Prostate volume (mL)   39.2±21.7
   \< 30                 97 (44.5)
   ≥ 30                  121 (55.5)
  PSA (ng/mL)            4.6±5.4
   \< 1.5                75/217 (34.6)
   ≥ 1.5                 142/217 (65.4)
  IPSS                   17.3±7.9
   0--19                 123/200 (61.5)
   ≥ 20                  77/200 (38.5)

Values are presented as mean standard error or number (%).

PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score.

###### 

Sequences for PCR

  SNPs          Sense primer             Antisense primer           PCR product size (bp)
  ------------- ------------------------ -------------------------- -----------------------
  EGF                                                               
   rs3756261    CGCCTGGCTAACTTTTTGTATT   TTACATGTCACCTGGGCTAATG     360
   rs11568835   ATCCAAACAGAACAGAGCTGTG   GCTCTGAACCCTTACAGGAGAA     329
   rs11568943   CACAGTGGCTCACACCTGTAAT   GGAAAATCAATTCTTCCTTGAC     364
   rs2237051    AGTCGGTGGCTCACTCATAACT   CAGCCAAGGAAAGACTGTGTAA     351
   rs11569017   CATCTTCAAACCCACTTGTGAA   CACTATAAATGGGGAGGTGGAG     446
  EGFR                                                              
   rs6965469    GTTCAGCAAACCCATTCTTCTC   CCTGTGCATTCACTTAACAAGG     352
   rs2293347    AACAAAATTGGCAAACACACAG   GACACAGCTTGAGAGAGAGAGAGA   323
   rs1050171    CGCATTCATGCGTCTTCACCTG   ATGGCAAACTCTTGCTATCCCA     368

PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism; EGF, growth factor receptor; EGFR, epidermal growth factor receptor.

###### 

Genotype and allele distributions of tested SNPs in groups according to prostate volume

  SNP           Genotype   Prostate volume (mL), n (%)   Model        OR (95% CI)    P-value              P-value^[a)](#tfn2-inj-1632538-269){ref-type="table-fn"}^   
  ------------- ---------- ----------------------------- ------------ -------------- -------------------- ----------------------------------------------------------- -------
  EGF           A/A        49 (50.5)                     75 (62.0)    Codominant1    0.70 (0.40--1.24)    0.220                                                       
   rs3756261    A/G        43 (44.3)                     42 (34.7)    Codominant2    0.55 (0.14--2.18)    0.400                                                       0.490
   -1744        G/G        5 (5.2)                       4 (3.3)      Dominant       0.68 (0.39--1.19)    0.180                                                       
                                                                      Recessive      0.64 (0.17--2.48)    0.520                                                       0.520
                                                                      Log-additive   0.72 (0.45--1.15)    0.170                                                       
                A          141 (72.7)                    192 (79.3)                  1                                                                                
                G          53 (27.3)                     50 (20.7)                   0.69 (0.45--1.08)    0.110                                                       
  EGF           G/G        63 (64.9)                     79 (65.3)    Codominant1    1.01 (0.56--1.85)    0.960                                                       
   rs11568835   G/A        28 (28.9)                     37 (30.6)    Codominant2    0.67 (0.19--2.30)    0.520                                                       0.550
   -1380        A/A        6 (6.2)                       5 (4.1)      Dominant       0.95 (0.54--1.68)    0.870                                                       0.550
                                                                      Recessive      0.66 (0.19--2.26)    0.510                                                       
                                                                      Log-additive   0.91 (0.58--1.45)    0.700                                                       
                G          154 (79.4)                    195 (80.6)                  1                                                                                
                A          40 (20.6)                     47 (19.4)                   0.93 (0.58--1.49)    0.760                                                       
  EGF           G/G        50 (51.5)                     80 (66.1)    Codominant1    0.64 (0.36--1.14)    0.130                                                       
   rs11568943   G/A        42 (43.3)                     39 (32.2)    Codominant2    0.25 (0.05--1.37)    0.110                                                       0.120
   Arg431Lys    A/A        5 (5.2)                       2 (1.6)      Dominant       0.60 (0.34--1.04)    0.070                                                       
                                                                      Recessive      0.30 (0.06--1.60)    0.140                                                       0.250
                                                                      Log-additive   0.60 (0.36--0.98)    0.038^[\*](#tfn1-inj-1632538-269){ref-type="table-fn"}^     
                G          142 (73.2)                    199 (82.2)                  1                                                                                
                A          52 (26.8)                     43 (17.8)                   0.59 (0.37--0.93)    0.024^[\*](#tfn1-inj-1632538-269){ref-type="table-fn"}^     
  EGF           A/A        47 (48.5)                     63 (52.1)    Codominant1    0.68 (0.39--1.20)    0.190                                                       
   rs2237051    A/G        47 (48.5)                     46 (38.0)    Codominant2    2.93 (0.77--11.09)   0.110                                                       0.160
   Met708Ile    G/G        3 (3.1)                       12 (9.9)     Dominant       0.82 (0.47--1.41)    0.460                                                       
                                                                      Recessive      3.49 (0.95--12.86)   0.040                                                       0.060
                                                                      Log-additive   1.05 (0.68--1.63)    0.830                                                       
                A          141 (72.7)                    172 (71.1)                  1                                                                                
                G          53 (27.3)                     70 (28.9)                   1.08 (0.71--1.65)    0.710                                                       
  EGF           A/A        44 (45.4)                     75 (62.0)    Codominant1    0.57 (0.32--1.00)    0.050                                                       
   rs11569017   A/T        47 (48.5)                     42 (34.7)    Codominant2    0.40 (0.11--1.50)    0.170                                                       0.180
   Asp784Val    T/T        6 (6.2)                       4 (3.3)      Dominant       0.55 (0.32--0.95)    0.031^[\*](#tfn1-inj-1632538-269){ref-type="table-fn"}^     
                                                                      Recessive      0.51 (0.14--1.88)    0.300                                                       0.350
                                                                      Log-additive   0.59 (0.37--0.95)    0.028^[\*](#tfn1-inj-1632538-269){ref-type="table-fn"}^     
                A          135 (69.6)                    192 (79.3)                  1                                                                                
                T          59 (30.4)                     50 (20.7)                   0.60 (0.39--0.92)    0.020^[\*](#tfn1-inj-1632538-269){ref-type="table-fn"}^     
  EGFR          C/C        63 (64.9)                     84 (69.4)    Codominant1    0.86 (0.47--1.57)    0.620                                                       
   rs6965469    C/T        29 (29.9)                     34 (28.1)    Codominant2    0.43 (0.10--1.88)    0.260                                                       0.300
   -2004        T/T        5 (5.2)                       3 (2.5)      Dominant       0.79 (0.45--1.41)    0.430                                                       
                                                                      Recessive      0.45 (0.10--1.95)    0.280                                                       0.470
                                                                      Log-additive   0.77 (0.47--1.26)    0.300                                                       
                C          155 (79.9)                    202 (83.5)                  1                                                                                
                T          39 (20.1)                     40 (16.5)                   0.79 (0.48--1.28)    0.340                                                       
  EGFR          G/G        44 (45.4)                     59 (48.8)    Codominant1    1.04 (0.58--1.85)    0.890                                                       
   rs2293347    G/A        41 (42.3)                     52 (42.9)    Codominant2    0.62 (0.24--1.59)    0.320                                                       
   Asp994Asp    A/A        12 (12.4)                     10 (8.3)     Dominant       0.94 (0.54--1.62)    0.820                                                       
                                                                      Recessive      0.61 (0.25--1.50)    0.280                                                       
                                                                      Log-additive   0.87 (0.58--1.31)    0.510                                                       
                G          129 (66.5)                    170 (70.2)                  1                                                                                
                A          65 (33.5)                     72 (29.8)                   0.84 (0.56--1.26)    0.400                                                       
  EGFR          G/G        75 (77.3)                     97 (80.2)    Codominant1    0.91 (0.47--1.78)    0.800                                                       
   rs1050171    G/A        21 (21.6)                     24 (19.8)    Codominant2    0.00 (0.00--NA)      1.000                                                       0.440
   Gln787Gln    A/A        1 (1.1)                       0 (0.0)      Dominant       0.88 (0.45--1.71)    0.710                                                       
                                                                      Recessive      0.00 (0.00--NA)      0.270                                                       0.450
                                                                      Log-additive   0.85 (0.45--1.61)    0.610                                                       
                G          171 (88.1)                    218 (90.1)                  1                                                                                
                A          23 (11.9)                     24 (9.9)                    0.82 (0.45--1.50)    0.520                                                       

SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; EGF, growth factor receptor; EGFR, epidermal growth factor receptor.

P\<0.05, statistically significant.

Fisher exact test.

###### 

Genotype and allele distributions of tested SNPs in groups according to PSA level

  SNP           Genotype   PSA (ng/mL), n (%)   Model        OR (95% CI)    P-value              P-value^[a)](#tfn4-inj-1632538-269){ref-type="table-fn"}^   
  ------------- ---------- -------------------- ------------ -------------- -------------------- ----------------------------------------------------------- -------
  EGF           A/A        33 (44.0)            91 (64.1)    Codominant1    0.48 (0.26-0.87)     0.016^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
   rs3756261    A/G        38 (50.7)            46 (32.4)    Codominant2    0.48 (0.12-1.91)     0.300                                                       0.260
   -1744        G/G        4 (5.3)              5 (3.5)      Dominant       0.48 (0.27-0.86)     0.013^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
                                                             Recessive      0.66 (0.17-2.56)     0.550                                                       0.500
                                                             Log-additive   0.56 (0.34-0.91)     0.020^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
                A          104 (69.3)           228 (80.3)                  1                                                                                
                G          46 (30.7)            56 (19.7)                   0.56 (0.35-0.87)     0.011^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
  EGF           G/G        47 (62.7)            94 (66.2)    Codominant1    0.93 (0.50-1.76)     0.830                                                       
   rs11568835   G/A        22 (29.3)            43 (30.3)    Codominant2    0.41 (0.12-1.43)     0.160                                                       0.190
   -1380        A/A        6 (8.0)              5 (3.5)      Dominant       0.82 (0.45-1.49)     0.520                                                       
                                                             Recessive      0.42 (0.12-1.44)     0.170                                                       0.200
                                                             Log-additive   0.77 (0.48-1.25)     0.290                                                       
                G          116 (77.3)           231 (81.3)                  1                                                                                
                A          34 (22.7)            53 (18.7)                   0.78 (0.48-1.27)     0.320                                                       
  EGF           G/G        36 (48.0)            94 (66.2)    Codominant1    0.52 (0.29-0.94)     0.031^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
   rs11568943   G/A        36 (48.0)            44 (31.0)    Codominant2    0.52 (0.11-2.46)     0.410                                                       0.410
   Arg431Lys    A/A        3 (4.0)              4 (2.8)      Dominant       0.52 (0.29-0.93)     0.027^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
                                                             Recessive      0.68 (0.15-3.15)     0.620                                                       0.700
                                                             Log-additive   0.58 (0.35-0.97)     0.036^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
                G          108 (72.0)           232 (81.7)                  1                                                                                
                A          42 (28.0)            52 (18.3)                   0.58 (0.36-0.92)     0.021^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
  EGF           A/A        40 (53.3)            70 (49.3)    Codominant1    1.01 (0.56-1.81)     0.980                                                       
   rs2237051    A/G        32 (42.7)            60 (42.2)    Codominant2    2.23 (0.59-8.46)     0.240                                                       0.260
   Met708Ile    G/G        3 (4.0)              12 (8.4)     Dominant       1.11 (0.63-1.96)     0.720                                                       
                                                             Recessive      2.22 (0.60-8.21)     0.200                                                       0.270
                                                             Log-additive   1.21 (0.76-1.92)     0.430                                                       
                A          112 (74.7)           200 (70.4)                  1                                                                                
                G          38 (25.3)            84 (29.6)                   1.24 (0.79-1.94)     0.350                                                       
  EGF           A/A        33 (44.0)            86 (60.6)    Codominant1    0.55 (0.30-0.99)     0.050                                                       
   rs11569017   A/T        38 (50.7)            50 (35.2)    Codominant2    0.59 (0.15-2.24)     0.440                                                       0.470
   Asp784Val    T/T        4 (5.3)              6 (4.2)      Dominant       0.55 (0.31-0.99)     0.044^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
                                                             Recessive      0.77 (0.21-2.85)     0.700                                                       0.740
                                                             Log-additive   0.64 (0.39-1.03)     0.070                                                       
                A          104 (69.3)           222 (78.2)                  1                                                                                
                T          46 (30.7)            62 (21.8)                   0.63 (0.40-0.99)     0.044^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
  EGFR          C/C        47 (62.7)            100 (70.4)   Codominant1    0.77 (0.41-1.46)     0.430                                                       
   rs6965469    C/T        23 (30.7)            39 (27.5)    Codominant2    0.27 (0.06-1.16)     0.080                                                       0.120
   -2004        T/T        5 (6.7)              3 (2.1)      Dominant       0.68 (0.37-1.24)     0.210                                                       
                                                             Recessive      0.29 (0.07-1.24)     0.090                                                       0.130
                C          117 (78.0)           239 (84.2)   Log-additive   0.65 (0.39-1.08) 1   0.100                                                       
                T          33 (22.0)            45 (15.8)                   0.67 (0.41-1.10)     0.110                                                       
  EGFR          G/G        41 (54.7)            61 (42.9)    Codominant1    1.61 (0.88-2.96)     0.120                                                       
   rs2293347    G/A        30 (40.0)            63 (44.4)    Codominant2    3.20 (0.99-10.35)    0.050                                                       0.060
   Asp994Asp    A/A        4 (5.3)              18 (12.7)    Dominant       1.81 (1.01-3.23)     0.044^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
                                                             Recessive      2.56 (0.82-7.98)     0.080                                                       0.100
                                                             Log-additive   1.70 (1.07-2.71)     0.020                                                       
                G          112 (74.7)           185 (65.1)                  1                                                                                
                A          38 (25.3)            99 (34.9)                   1.58 (1.01-2.45)     0.043^[\*](#tfn3-inj-1632538-269){ref-type="table-fn"}^     
  EGFR          G/G        55 (73.3)            116 (81.7)   Codominant1    0.67 (0.34-1.32)     0.250                                                       
   rs1050171    G/A        19 (25.3)            26 (18.3)    Codominant2    0.00 (0.00-NA)       1.000                                                       0.330
   Gln787Gln    A/A        1 (1.4)              0 (0.0)      Dominant       0.64 (0.33-1.26)     0.200                                                       
                                                             Recessive      0.00 (0.00-NA)       0.200                                                       0.360
                                                             Log-additive   0.62 (0.32-1.19)     0.150                                                       
                G          129 (86.0)           258 (90.8)                  1                                                                                
                A          21 (14.0)            26 (9.2)                    0.62 (0.34-1.14)     0.130                                                       

SNP, single nucleotide polymorphism; PSA, prostate-specific antigen; OR, odds ratio; CI, confidence interval; EGF, growth factor receptor; EGFR, epidermal growth factor receptor.

P\<0.05, statistically significant.

Fisher exact test.

###### 

Haplotype analysis in rs11568943, rs2237051, and rs11569017 of *EGF* gene

  Haplotype   Frequency   Group 1                     Group 2                    Chi-square   P-value           
  ----------- ----------- --------------------------- -------------------------- ------------ --------- ------- ---------------------------------------------------------
                          Prostate volume (\<30 mL)   Prostate volume (≥30 mL)                                  
  GAA         0.468       82                          112                        122          120       2.869   0.090
  GGA         0.280       53                          141                        69           173       0.077   0.780
  AAT         0.215       52                          142                        42           200       5.679   0.017^[\*](#tfn5-inj-1632538-269){ref-type="table-fn"}^
  GAT         0.035       7                           187                        8            234       0.031   0.860
                          PSA (\< 1.5 ng/mL)          PSA (≥ 1.5 ng/mL)                                         
  GAA         0.470       66                          84                         138          146       0.831   0.360
  GGA         0.279       38                          112                        83           201       0.741   0.390
  AAT         0.214       42                          108                        51           233       5.876   0.015^[\*](#tfn5-inj-1632538-269){ref-type="table-fn"}^
  GAT         0.035       4                           146                        11           273       0.424   0.520

PSA, prostate-specific antigen.

P\<0.05, statistically significant.

[^1]: These authors contributed equally to this study and should be considered co-first authors.
